The USPTO’s Patent Trial and Appeal Board has agreed to review the validity of U.S. Patent No. 9,795,604 covering methods of treating graft-versus-host disease with AbbVie’s (NYSE:ABBV) [and Johnson and Johnson’s (NYSE:JNJ)] Imbruvica (ibrutinib).
Novartis (NYSE:NVS) unit Sandoz is challenging.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.